Breaking News Instant updates and real-time market news.

OSTK

Overstock.com

$22.01

0.01 (0.05%)

, ENPH

Enphase Energy

$8.38

-0.33 (-3.79%)

08:45
03/07/19
03/07
08:45
03/07/19
08:45

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: Overstock com (OSTK) 30.20% +1.08, Enphase Energy (ENPH) 6.98% +0.30, Turtle Beach (HEAR) 43.84% +0.14, Bristow Group (BRS) 18.15% +0.12, Sears (SHLDQ) 118.99% +0.10, Accelerate Diagnostics (AXDX) 39.86% +0.05, Novavax (NVAX) 1.39% +0.04, YETI Holdings (YETI) 7.40% +0.03, FXI (FXI) 0.30% +0.03, and Intelsat (I) 0.42% +0.02.

OSTK

Overstock.com

$22.01

0.01 (0.05%)

ENPH

Enphase Energy

$8.38

-0.33 (-3.79%)

HEAR

Turtle Beach

$15.89

-0.17 (-1.06%)

BRS

Bristow Group

$1.02

-0.09 (-8.11%)

AXDX

Accelerate Diagnostics

$20.64

-0.71 (-3.33%)

NVAX

Novavax

$0.57

-0.0282 (-4.72%)

YETI

Yeti

$24.00

-0.06 (-0.25%)

FXI

iShares China Large-Cap ETF

$44.51

-0.46 (-1.02%)

I

Intelsat

$18.26

0.52 (2.93%)

  • 11

    Mar

  • 19

    Mar

  • 28

    May

OSTK Overstock.com
$22.01

0.01 (0.05%)

02/12/19
DADA
02/12/19
NO CHANGE
Target $60
DADA
Underperform
DA Davidson reiterates $60 target on Wayfair citing Amazon 'encroachment'
In a research earlier today titled "Encroachment Is a 5-Yard Penalty," DA Davidson analyst Tom Forte reiterated an Underperform rating on Wayfair with a $60 12-18 month price target. The stock in morning trading is up 1% to $120.89. Amazon.com (AMZN) announced yesterday that it was launching two private-label furniture brands in the U.K., Forte wrote to investors. The analyst sees the news as "yet another indication" of Amazon's intent to expand its efforts in the home category, including furniture. Yesterday's announcement follows Amazon's decision last December to lower third-party selling fees for the furniture category, the analyst points out. Forte views Amazon's efforts to ramp its sales in the home category as an increasing threat for Wayfair. Further, the analyst is monitoring the potential sale of Overstock's (OSTK) legacy home e-commerce business, as he thinks a sale to a large bricks and mortar retailer could also result in additional competition for Wayfair.
01/25/19
DADA
01/25/19
NO CHANGE
Target $58
DADA
Buy
Overstock.com's tZERO an 'incredibly valuable asset,' says DA Davidson
DA Davidson analyst Tom Forte reiterated a Buy rating and $58 price target on Overstock.com. In a research note to investors, Forte says he continues to view tZERO as an "incredibly valuable asset" and sees that the secondary trading of security tokens is an "important" accomplishment on the way to popularizing the tokenization of assets.
12/18/18
DADA
12/18/18
NO CHANGE
Target $58
DADA
Buy
Overstock.com price target lowered to $58 from $112 at DA Davidson
DA Davidson analyst Tom Forte slashed his price target on Overstock.com to $58 after the company's disclosure to investors that it was unable to finalize its GSR Ventures transaction by its mid-December target yesterday, pushing that deadline to February of next year. The analyst notes that investors responded to this management stumble by sending the stock price down over 20% from what he sees as "already depressed levels". Forte still keeps his Buy rating on Overstock.com, but states that his new valuation methodology is based on more of a "crawl, walk, run approach", even though he still values the company's 80% tZero holdings at a $1B valuation that equates to $27 per share and its retail business at 31 per share.
12/21/18
DADA
12/21/18
NO CHANGE
Target $58
DADA
Buy
DA Davidson sees encouraging signs for Overstock despite GSR disappointment
DA Davidson analyst Tom Forte said while he recognizes the recent disappointment regarding Overstock's inability to close its transactions with GSR Ventures, he is also seeing encouraging signs for the company's blockchain-related investments. "Lost in the disappointment of Monday" was the announcement that GSR Ventures and tZERO intend to work together to tokenize cobalt, which he sees as one example of potentially many regarding its ability to play an instrumental role in the creation and trading of tokens, Forte tells investors. He reiterates a Buy rating and $58 price target on Overstock shares and recommends purchasing at current levels, noting that his target includes a $31 per share valuation for its legacy home e-commerce business and $27 for its Medici Ventures portfolio of 19 blockchain companies, most of that being attributable to tZERO.
ENPH Enphase Energy
$8.38

-0.33 (-3.79%)

02/21/19
COWN
02/21/19
NO CHANGE
Target $9
COWN
Outperform
Enphase Energy price target raised to $8.50 from $6.75 at Cowen
Cowen analyst Jeffrey Osborne raised his price target on Enphase Energy to $8.50 from $6.75 ahead of Q4 results. The analyst believes both the results and guidance will be in-line with expectations, but he said long lead times due to component supply tightness will impede growth in the near term. Osborne reiterated his Outperform rating on Enphase Energy shares.
09/19/18
ROTH
09/19/18
NO CHANGE
ROTH
Buy
Tariff exemption a 'meaningful positive' for SunPower, Enphase, says Roth
Roth Capital analyst Philip Shen tells investors in a research note that SunPower's (SPWR) exclusion from the 30% Section 201 import tariffs for its IBC cells and modules is a "meaningful positive" for the company, as with the exclusion, SunPower appears to be the only company to serve the U.S. resi market with tariff-free modules imported from outside the U.S., except for First Solar (FSLR), which does not serve the resi market. In addition, Shen views the news as a meaningful positive for Enphase (ENPH) given its exclusive relationship with SunPower, and says Enphase could benefit from increased volumes ahead.
09/18/18
VERF
09/18/18
NO CHANGE
VERF
Latest tariffs incremenally negative for SolarEdge, Enphase, says Vertical Group
Vertical Group analyst Gordon Johnson said the latest round of tariffs being imposed by the U.S. on Chinese imports are an incremental negative for solar inverter companies with owned and/or outsourced manufacturing capacity in China, such as SolarEdge (SEDG) and Enphase Energy (ENPH). He also thinks the escalating U.S. trade war with China offers a competitive advantage to European-based manufacturers that have recently converted their technology, such as ABB (ABB). At the very least, inverter prices are set to increase at least 10% if distributors do not shift demand over to more traditional string-based suppliers, Johnson tells investors.
08/01/18
RILY
08/01/18
NO CHANGE
Target $7.5
RILY
Buy
Enphase Energy weakness a buying opportunity, says B. Riley FBR
B. Riley FBR analyst Carter Driscoll views the post-earnings weakness in shares of Enphase Energy as a buying opportunity. Enphase rebuked the short report and the upcoming analyst day, which will unveil a differentiated iQ8 microinverter, provides catalysts, Driscoll tells investors in a research note. He keeps a Buy rating on the shares with a $7.50 price target.
HEAR Turtle Beach
$15.89

-0.17 (-1.06%)

12/07/18
DADA
12/07/18
NO CHANGE
Target $30
DADA
Buy
Turtle Beach benefits from Fortnite Season 7 launch yesterday, says DA Davidson
DA Davidson analyst Tom Forte kept his Buy rating and $30 price target on Turtle Beach (HEAR), saying investors should buy the stock after the launch of the latest Fortnite season 7 yesterday. The analyst contends that Fortnite developer - Epic Games - has continued to refine the title over time, giving it "staying power" that's reflected by its 200M user milestone reached last month. Forte continues to anticipate the sustained Fortnite popularity to result in "elevated sales of gaming headsets", which should be positive news for Turtle Beach and Logitech (LOGI).
11/26/18
WEDB
11/26/18
NO CHANGE
WEDB
Wedbush Black Friday checks positive for Consumer Electronics, Turtle Beach
Wedbush Retail analysts led by Michael Pachter say their Black Friday channel checks were positive for Consumer Electronics with Turtle Beach (HEAR) a "stand-out." Fitbit (FIT) and GoPro (GPRO) offered more compelling discounts on new products this year versus last year, which likely drove more unit sales, the analysts write in a research note. Further, they believe Amazon (AMZN) took Smart TV market share as its Fire TV Edition Smart TVs were not available at retail last year. Nonetheless, with more favorable pricing this year across brands and greater breadth of products, Roku TV (ROKU) unit sales were likely higher versus last year, say the analysts. And despite high inventory going into Black Friday, Turtle Beach had low inventory levels with "spotty" sell-outs on Black Friday, they note. The analysts believe this suggests a "very strong uptick" in year-over-year holiday sales for the company.
11/28/18
DADA
11/28/18
NO CHANGE
Target $30
DADA
Buy
Turtle Beach to benefit from continued popularity of Fortnite, says DA Davidson
DA Davidson analyst Tom Forte kept his Buy rating and $30 price target on Turtle Beach (HEAR), saying the recent Bloomberg article indicating 200M active Fortnite gamers - up from 125M in June - suggests that its popularity is not a "fad". The analyst believes that this growth should result in "elevated sales of gaming headsets, which should be positive news for Turtle Beach primarily and Logitech (LOGI) secondarily. Forte adds that the initial success of the latest Call of Duty title and Red Dead Redemption 2, which are also games with battle royale playing formats, will sustain demand for the Turtle Beach accessories.
02/07/19
LSCM
02/07/19
NO CHANGE
LSCM
Turtle Beach releases better-than-expected Q4 preannouncement, says Lake Street
Lake Street analyst Mark Argento maintained a Buy rating and $40 price target on Turtle Beach, after the company's Q4 preannouncement was "significantly ahead" of both consensus estimates and the company's guidance. The analyst noted that Turtle Beach's market share expanded in FY18, that the company generated significant free cash flow in FY18, and that the company is expecting strong gross margin in Q4 and for FY18. Argento believes Turtle Beach's FY19 will be closer to FY18 than FY17, given the company's expansion and larger installed base of hardware.
BRS Bristow Group
$1.02

-0.09 (-8.11%)

AXDX Accelerate Diagnostics
$20.64

-0.71 (-3.33%)

11/07/18
JPMS
11/07/18
DOWNGRADE
Target $16
JPMS
Neutral
Accelerate Diagnostics downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Tycho Peterson downgraded Accelerate Diagnostics to Neutral and lowered his price target for the shares to $16 from $25. The analyst says Q3 did not bring what he was hoping for given "another miss and pipeline delay."
02/20/19
PIPR
02/20/19
NO CHANGE
Target $22
PIPR
Overweight
Accelerate Diagnostics price target raised to $22 from $17 at Piper Jaffray
Piper Jaffray analyst William Quirk raised his price target for Accelerate Diagnostics to $22 after the company reported Q4 revenue inline with its preannouncement. The analyst continues to believe the reagent rental shift is the correct market approach for Pheno, and looks forward to increasing placements in the coming quarters. He keeps an Overweight rating on Accelerate Diagnostics.
01/11/19
PIPR
01/11/19
NO CHANGE
Target $17
PIPR
Overweight
Accelerate Diagnostics price target lowered to $17 from $21 at Piper Jaffray
Piper Jaffray analyst William Quirk lowered his price target for Accelerate Diagnostics to $17 after the company reported revenue guidance below consensus. Strong instrument placements were offset by the shift to the reagent rental business model, Quirk tells investors in a research note. The analyst, however, still believes Pheno can revolutionize the microbiology market and that the reagent rental model is the correct long-term approach for Accelerate, justifying a premium multiple. He keeps an Overweight rating on Accelerate Diagnostics.
11/07/18
JPMS
11/07/18
DOWNGRADE
Target $16
JPMS
Neutral
JPMorgan downgrades Accelerate to Neutral on 'significant miss,' pipeline delay
JPMorgan analyst Tycho Peterson downgraded Accelerate Diagnostics to Neutral from Overweight and lowered his price target for the shares to $16 from $25. The company last night announced another significant miss despite again processing record-high system placement as it continues to be bottlenecked by hospital budget constraints, Peterson tells investors in a post-earnings research note. Peterson, who remains encouraged by the long-term potential of the flagship Pheno instrument, says the uptake post-launch a year ago have been much weaker than originally anticipated. In addition, despite expectations for the severe bacterial pneumonia test to start clinical trial testing in Q3, Accelerate registered "yet another delay" due to FDA pushback tied to the lack of reproducibility, and now expects to start the clinical trial in Q1 of 2019, the analyst adds. He downgrades the shares to Neutral citing "another disappointing quarter" with "yet another unexpected pipeline delay."
NVAX Novavax
$0.57

-0.0282 (-4.72%)

03/01/19
HCWC
03/01/19
NO CHANGE
Target $2
HCWC
Buy
'Strong' investment thesis remains for buying Novavax, says H.C. Wainwright
A "strong" investment thesis remains for buying Novavax shares, H.C. Wainwright analyst Vernon Bernardino tells investors in a research note. He reiterates a Buy rating on the stock with a $2 price target. Novavax closed yesterday down 67%, or $1.42, to 71c. ResVax, despite the failed Phase 3 study, showed efficacy in hospitalizations and lower respiratory tract infections with severe hypoxemia, which are likely the most clinically relevant measures over the first 180 days of life in infants in the study, Bernardino contends. The analyst looks for discussions with the FDA and European regulators, which are expected in the next 90 days, to be positive for the completion of ResVax's "pathway to regulatory approval."
02/28/19
JPMS
02/28/19
DOWNGRADE
JPMS
Underweight
Novavax downgraded to Underweight from Overweight at JPMorgan
JPMorgan analyst Eric Joseph double downgraded Novavax to Underweight from Overweight saying he sees a "limited path forward" following the on RexVax Phase 3 failure.
02/28/19
PIPR
02/28/19
DOWNGRADE
Target $0.25
PIPR
Underweight
Piper double downgrades Novavax to Underweight with 25c target after trial miss
Piper Jaffray analyst Edward Tenthoff double downgraded Novavax to Underweight from Overweight and cut his price target for the shares to 25c from $4.50. The stock in premarket trading is down 65%, or $1.38, to 75c after the Phase III Prepare maternal immunization trial of ResVax missed the primary endpoint. While Novavax plans to meet with regulators, Tenthoff does not see a clear path to registration. Importantly, Novavax ended Q3 with cash of $145.6M and retains a $325M convert due in February 2023, the analyst tells investors in a research note. The company recently reported positive Phase II immunogenicity data on NanoFlu, but would need to find funding to conduct a Phase III trial, he points out.
03/04/19
RILY
03/04/19
NO CHANGE
Target $1.75
RILY
Buy
Novavax flu vaccine potential being overlooked, say B. Riley FBR
Investors did not interpret Novavax's trial results for its respiratory syncytial virus vaccine properly and are overlooking its flu vaccine potential, B. Riley FBR analyst George Zavoico tells investors in a research note. Prepare would have been a successful registrational Phase III trial if it had incorporated some minor design changes understood now but unknown when the trial was planned, says the analyst. He points out that Novavax will meet with the FDA in the next 30-90 days to present a case for accepting a biologics license application for review this year, based on "robust" vaccine efficacy reported for clinically meaningful secondary endpoints. Zavoico ascribes a low probability to this outcome, but notes it would be a game-changer for Novavax if the FDA makes a decision to review a ResVax BLA, based only on the available data set. He lowered his price target for the shares to $1.75 from $10 and keeps a Buy rating on the name.
YETI Yeti
$24.00

-0.06 (-0.25%)

02/14/19
BARD
02/14/19
NO CHANGE
Target $23
BARD
Outperform
Yeti results show bullish thesis intact, says Baird
Baird analyst Peter Benedict said Yeti had a solid finish to 2018 and Q4 results were "way ahead" of his estimates. He said the company maintains an attractive top-line growth profile and impressive free cash flow. Benedict, who said the results show his bullish thesis remains intact, reiterated his Outperform rating and $23 price target on Yeti shares.
02/15/19
MSCO
02/15/19
NO CHANGE
Target $26
MSCO
Overweight
Morgan Stanley says Yeti story underappreciated, ups price target to $26
Morgan Stanley analyst Kimberly Greenberger raised her 2019 EBITDA estimate for Yeti to $160.4M from $150.6M after the company reported a "strong" Q4 and gave 2019 guidance that was better than her forecast and the consensus view. She believes the stock remains "underappreciated" and "looks compelling" even after its 18% move up following the report. Greenberger increased her price target on Yeti shares to $26 from $21 and maintains an Overweight rating on the stock.
02/15/19
PIPR
02/15/19
NO CHANGE
Target $28
PIPR
Overweight
Piper continues to see value in Yeti shares, ups target to $28
Piper Jaffray analyst Peter Keith raised his price target for Yeti to $28 citing the company's "positive" Q4 earnings call and 2019 guidance that was above the Street. Yeti continues to see "solid" momentum in the brand and its first national ad campaign in Q4 seemed to drive awareness and traffic to its site, Keith tells investors in a post-earnings research note. The analyst believes the company remains in early days of its brand expansion, and he continues to see value in the shares. Keith reiterates an Overweight rating on Yeti.
02/14/19
BARD
02/14/19
NO CHANGE
BARD
Yeti price target raised to $26 from $23 at Baird
Baird analyst Peter Benedict reiterated an Outperform rating on Yeti, and raised his price target on shares to $26 from $23. The analyst sees significant upside for the stock, even the strong move in the stock today. Benedict said, "With an authentic/premium brand, broadening customer appeal, and long runway for geographic expansion, Yeti appears poised to generate solid double-digit top- and bottom-line growth over the next several years."
FXI iShares China Large-Cap ETF
$44.51

-0.46 (-1.02%)

I Intelsat
$18.26

0.52 (2.93%)

03/05/19
RBCM
03/05/19
NO CHANGE
Target $57
RBCM
Outperform
Intelsat pullback on 'noise' a 'great buying opportunity,' says RBC Capital
RBC Capital analyst Wilton Fry blames three distinct stories for the pullback over the last two days in shares of Intelsat - a report from Politico on Friday about efforts toward 5G nationalization; comments made by Senator Mike Doyle regarding a call for a reintroduction of the Airwaves Act; and the resignation of Preston Padden as the Head of Advocacy and Government Relations at the C Band Alliance. However, he regards the perceived issues as "noise" and believes the pullback is a "great buying opportunity," Fry tells investors. He reiterates an Outperform rating and $57 price target on Intelsat shares.
03/06/19
03/06/19
UPGRADE

Market Perform
Intelsat upgraded to Market Perform on valuation at Raymond James
As previously reported, Raymond James upgraded Intelsat to Market Perform from Underperform. Analyst Ric Prentiss believes Intelsat's valuation more appropriately reflects a reasonable @/Mhz Pop net price valuation for the possible monetization opportunity.
03/06/19
RAJA
03/06/19
UPGRADE
RAJA
Market Perform
Intelsat upgraded to Market Perform from Underperform at Raymond James
02/25/19
EVER
02/25/19
INITIATION
Target $50
EVER
Outperform
Intelsat initiated with an Outperform at Evercore ISI
Evercore initiated Intelsat with an Outperform and $50 price target.

TODAY'S FREE FLY STORIES

SPY

SPDR S&P 500 ETF Trust

$300.59

-0.09 (-0.03%)

, SPX

S&P 500

$0.00

(0.00%)

14:29
07/15/19
07/15
14:29
07/15/19
14:29
General news
Mnuchin said he thinks a budget deal is 'close' »

Treasury Secretary Steve…

SPY

SPDR S&P 500 ETF Trust

$300.59

-0.09 (-0.03%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$300.57

-0.11 (-0.04%)

, SPX

S&P 500

$0.00

(0.00%)

14:27
07/15/19
07/15
14:27
07/15/19
14:27
General news
Mnuchin says had 'very productive' talks with Pelosi on debt ceiling »

Treasury Secretary Steve…

SPY

SPDR S&P 500 ETF Trust

$300.57

-0.11 (-0.04%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LOGC

LogicBio Therapeutics

$12.55

0.41 (3.38%)

14:26
07/15/19
07/15
14:26
07/15/19
14:26
Conference/Events
LogicBio Therapeutics management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 19

    Jul

QURE

uniQure

$68.66

-1.74 (-2.47%)

14:25
07/15/19
07/15
14:25
07/15/19
14:25
Options
uniQure call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jul

  • 09

    Sep

AVGO

Broadcom

$290.65

5.26 (1.84%)

, SYMC

Symantec

$21.78

-3.78 (-14.79%)

14:21
07/15/19
07/15
14:21
07/15/19
14:21
Periodicals
Broadcom still keen to find solution as Symantec bid stalls over price, FT says »

Broadcom's (AVGO)…

AVGO

Broadcom

$290.65

5.26 (1.84%)

SYMC

Symantec

$21.78

-3.78 (-14.79%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

14:17
07/15/19
07/15
14:17
07/15/19
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

14:16
07/15/19
07/15
14:16
07/15/19
14:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KKR

KKR

$26.49

-0.32 (-1.19%)

14:15
07/15/19
07/15
14:15
07/15/19
14:15
Options
KKR put volume heavy and directionally bearish »

Bearish flow noted in KKR…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

14:15
07/15/19
07/15
14:15
07/15/19
14:15
General news
Fed funds futures are fractionally higher »

Fed funds futures are…

FB

Facebook

$203.96

-0.945 (-0.46%)

, BTC

Bitcoin

$0.00

(0.00%)

14:14
07/15/19
07/15
14:14
07/15/19
14:14
Hot Stocks
Mnuchin says Trump has cryptocurrency concerns, won't target a specific provider »

Asked about President…

FB

Facebook

$203.96

-0.945 (-0.46%)

BTC

Bitcoin

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jul

  • 17

    Jul

  • 24

    Jul

C

Citi

$71.87

0.12 (0.17%)

14:11
07/15/19
07/15
14:11
07/15/19
14:11
Hot Stocks
Citi reports June credit loss rate 2.56% vs. 2.74% last month »

Reports June 30-plus day…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Jul

  • 13

    Aug

FB

Facebook

$203.77

-1.135 (-0.55%)

14:09
07/15/19
07/15
14:09
07/15/19
14:09
Hot Stocks
Breaking Hot Stocks news story on Facebook »

Mnuchin says Facebook…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jul

  • 17

    Jul

  • 24

    Jul

FB

Facebook

$203.81

-1.095 (-0.53%)

, BTC

Bitcoin

$0.00

(0.00%)

14:07
07/15/19
07/15
14:07
07/15/19
14:07
Hot Stocks
Mnuchin says Treasury has 'serious concerns' about Facebook's Libra, bitcoin »

Treasury Secretary Steven…

FB

Facebook

$203.81

-1.095 (-0.53%)

BTC

Bitcoin

$0.00

(0.00%)

BITCOIN

Bitcoin

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jul

  • 17

    Jul

  • 24

    Jul

SCHW

Charles Schwab

$40.49

0.47 (1.17%)

14:05
07/15/19
07/15
14:05
07/15/19
14:05
Options
Charles Schwab call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

  • 27

    Oct

CSGP

CoStar Group

$583.45

-3.56 (-0.61%)

14:05
07/15/19
07/15
14:05
07/15/19
14:05
Hot Stocks
CoStar Group signs agreement with Behar Group Realty »

CoStar Group is pleased…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 12

    Aug

  • 13

    Nov

HTGC

Hercules Capital

$12.96

-0.02 (-0.15%)

14:00
07/15/19
07/15
14:00
07/15/19
14:00
Hot Stocks
Hercules Capital reports separation agreement with Manuel Henriquez »

In a regulatory filing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

GLPG

Galapagos

$170.88

25.21 (17.31%)

13:59
07/15/19
07/15
13:59
07/15/19
13:59
Downgrade
Galapagos rating change at Raymond James »

Galapagos downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

  • 09

    Sep

LVMUY

LVMH

$0.00

(0.00%)

13:52
07/15/19
07/15
13:52
07/15/19
13:52
Hot Stocks
LVMH announces partnership with Stella McCartney »

Stella McCartney and LVMH…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

SCHW

Charles Schwab

$40.49

0.47 (1.17%)

13:51
07/15/19
07/15
13:51
07/15/19
13:51
Recommendations
Charles Schwab analyst commentary  »

Wells says Schwab deal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

  • 27

    Oct

AMC

AMC Entertainment

$9.45

(0.00%)

13:45
07/15/19
07/15
13:45
07/15/19
13:45
Options
AMC Entertainment call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Sep

SPY

SPDR S&P 500 ETF Trust

$300.31

-0.37 (-0.12%)

, SPX

S&P 500

$0.00

(0.00%)

13:43
07/15/19
07/15
13:43
07/15/19
13:43
Periodicals
Trump ponders firing Commerce Secretary Wilbur Ross, NBC News says »

According to an earlier…

SPY

SPDR S&P 500 ETF Trust

$300.31

-0.37 (-0.12%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDCO

The Medicines Co.

$36.65

-0.03 (-0.08%)

13:35
07/15/19
07/15
13:35
07/15/19
13:35
Options
Medicines Company put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NTGN

Neon Therapeutics

$4.61

0.3 (6.96%)

13:30
07/15/19
07/15
13:30
07/15/19
13:30
Recommendations
Neon Therapeutics analyst commentary at Mizuho »

Neon Therapeutics'…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

SYMC

Symantec

$21.73

-3.83 (-14.98%)

, AVGO

Broadcom

$289.18

3.79 (1.33%)

13:27
07/15/19
07/15
13:27
07/15/19
13:27
Periodicals
Broadcom was willing to pay up $28.25 per share for Symantec, Reuters reports »

Symantec (SYMC) walked…

SYMC

Symantec

$21.73

-3.83 (-14.98%)

AVGO

Broadcom

$289.18

3.79 (1.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CARA

Cara Therapeutics

$25.55

1.25 (5.14%)

13:25
07/15/19
07/15
13:25
07/15/19
13:25
Options
Cara Therapeutics call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.